CVS Health Co. (NYSE:CVS - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2024 EPS estimates for CVS Health in a research report issued on Tuesday, December 31st. Cantor Fitzgerald analyst S. James now expects that the pharmacy operator will earn $5.19 per share for the year, down from their previous estimate of $5.29. Cantor Fitzgerald has a "Neutral" rating and a $62.00 price objective on the stock. The consensus estimate for CVS Health's current full-year earnings is $5.32 per share.
CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The pharmacy operator reported $1.09 EPS for the quarter, topping analysts' consensus estimates of $1.08 by $0.01. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The firm had revenue of $95.43 billion for the quarter, compared to analyst estimates of $92.72 billion. During the same quarter in the prior year, the firm earned $2.21 EPS. The company's revenue was up 6.3% on a year-over-year basis.
Other equities research analysts also recently issued research reports about the company. Wells Fargo & Company upgraded CVS Health from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $60.00 to $66.00 in a research report on Monday, November 18th. Piper Sandler cut their target price on shares of CVS Health from $72.00 to $64.00 and set an "overweight" rating on the stock in a research report on Monday, November 25th. Deutsche Bank Aktiengesellschaft upgraded shares of CVS Health from a "hold" rating to a "buy" rating and set a $66.00 price target for the company in a research report on Tuesday, December 3rd. UBS Group increased their price objective on shares of CVS Health from $60.00 to $62.00 and gave the company a "neutral" rating in a report on Thursday, November 7th. Finally, Barclays dropped their target price on shares of CVS Health from $75.00 to $71.00 and set an "overweight" rating for the company in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $69.12.
View Our Latest Analysis on CVS
CVS Health Trading Up 2.2 %
CVS stock traded up $0.95 during trading on Wednesday, hitting $44.89. The company had a trading volume of 11,683,349 shares, compared to its average volume of 11,647,537. The stock has a market cap of $56.49 billion, a price-to-earnings ratio of 11.39, a PEG ratio of 0.85 and a beta of 0.54. The company has a quick ratio of 0.59, a current ratio of 0.80 and a debt-to-equity ratio of 0.80. The firm has a 50-day moving average price of $53.30 and a 200-day moving average price of $57.30. CVS Health has a 12 month low of $43.56 and a 12 month high of $83.25.
Hedge Funds Weigh In On CVS Health
A number of large investors have recently added to or reduced their stakes in CVS. MidAtlantic Capital Management Inc. acquired a new stake in shares of CVS Health in the third quarter valued at approximately $25,000. Livelsberger Financial Advisory acquired a new stake in CVS Health in the 3rd quarter valued at $31,000. Legacy Investment Solutions LLC bought a new stake in CVS Health during the 3rd quarter worth about $31,000. Reston Wealth Management LLC acquired a new position in shares of CVS Health during the 3rd quarter worth about $32,000. Finally, Kathleen S. Wright Associates Inc. bought a new position in shares of CVS Health in the 3rd quarter valued at about $33,000. Institutional investors own 80.66% of the company's stock.
CVS Health Company Profile
(
Get Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Featured Articles
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
